Prevest Denpro Ltd. · BSE:PREVEST
Prevest Denpro — Q3 FY2022 Earnings Presentation
26 slides from Prevest Denpro's earnings presentation, Feb 1, 2022
Slide 1: Earnings Presentation: Q3 FY22
PREVEST DENPRO LIMITED “The Future of Dentistry” EARNINGS PRESENTATION: Q3 FY22 Image source: freepik.com Icon source: thenounproject.com www.prevestdenpro.com
Slide 2: Prevest at a Glance
PREVEST AT A GLANCE With over 21 years of experience in development and manufacture of innovative materials for dental professionals, Prevest DenPro Limited is one of the India’s leading manufacturer of dental materials serving the global dental market with a wide range of high quality dental materi
Slide 3: Product Portfolio
PRODUCT PORTFOLIO Product Categories No. of products Product Usage Endodontics Materials +25 Root canal treatment Cements & Liners +16 Luting and restorative applications Composites +8 Dental restoration and filling Orthodontics Materials +2 Used for Orthodontic applcations Finishing & Polishing +5
Slide 4: Wide Range of Over +100 Products
WIDE RANGE OF OVER +100 PRODUCTS 4 www.prevestdenpro.com
Slide 5: State of the Art Manufacturing Facility
STATE OF THE ART MANUFACTURING FACILITY The entire products are developed, manufactured and assembled in-house at Company’s Manufacturing unit located at EPIP Kartholi, Samba, near Jammu, J&K, sprawling in an area of 45,000 sq. ft. Particulars F.Y. 2019-20 F.Y. 2020-21 Installed capacity (in mt) 150
Slide 6: Diversification in New Product Segments
DIVERSIFICATION IN NEW PRODUCT SEGMENTS FORTHCOMING PRODUCTS Bio-materials Medicated ointments, Sanitizers and Mouth washes and (Bone grafting materials gels and creams for disinfectants Mouth rinses and membranes) dental treatment New Facility under construction for manufacturing new range of produ
Slide 7: Global Product Reach
GLOBAL PRODUCT REACH GEOGRAPHICAL WISE REVENUE FROM OPERATIONS DIGITAL MARKET PLATFORMS 9MFY2022 1% 5% 9% 21% TOTAL:- RS. 2,829 LAKHS 10% 54% Africa Asia Europe Middle east North America South America Export to over +90 +50 +80 Overseas Dealers in countries Agents India › Ready to enter in the Marke
Slide 8: Strategic Tie-ups and Quality Accreditations
STRATEGIC TIE-UPS AND QUALITY ACCREDATIONS The Company has entered into collaboration with the following reputed dental universities & institutions for exchange of technical knowledge and conducting training & research on dental materials. Terna Dental A.B. Shetty Memorial Army College of R.S.M.N. N
Slide 9: Competitive Strengths
COMPETITIVE STRENGTHS Well - established sales B2B and B2C Comprehensive Product Research Collaboration Strong Advisory Board network in over 75 Sales Model Portfolio with prominent & Management Countries academic institutes With consistent marketing Along with B2B Sales (i.e. In the last two decade
Slide 10: Experienced Management and Strong Advisory Board
EXPERIENCED MANAGEMENT AND STRONG ADVISORY BOARD Board of Directors Atul Modi Namrata Modi Dr. Sai Kalyan Surapaneni (Chairman and MD) (Whole Time Director and CFO) (Director) Experience: 44 years Experience: 22 years Experience: 18 years Qualification: BE (Mechanical) Qualification: MBA (Entreprene
Slide 11: Advisory Board
ADVISORY BOARD The company has constituted an advisory board comprising of industry recognized and esteemed dental professionals, scientists and researchers to augment the knowledge, understanding and strategic thinking of the Board members and Management team as well as to provide expert insights i
Slide 12: Operational Strategies
OPERATIONAL STRATEGIES Limiting competition with patenting The Company has filed patent application for two of its innovative products and further aims to secure patent rights for more products in the forthcoming years. Enter into Development high growth markets of R&D Centre The Company is all set
Slide 13: Awards and Recognitions
Gold Trophy Award by Federation of Indian Sushruta Award for ‘Make in India’ Best Dental Exporters Organization Manufacturer by Indian Dental Association (IDA) AWARDS AND RECOGNITIONS ‘Best Enterprise’ Award in the field of manufacture SME Excellence Award by Assocham of dental materials, India by t
Slide 14: Industry Scenario
INDUSTRY SCENARIO Image source: freepik.com Icon source: thenounproject.com 14 www.prevestdenpro.com Hem Securities Limited
Slide 15: Global Dental Material Market: Segmentation Analysis
GLOBAL DENTAL MATERIAL MARKET : SEGMENTATION ANALYSIS Product Type Application End User Region Indirect Restorative Materials › Endodontics › Dental Laboratories › North America › Metal-Ceramics › Prosthodontics › Dental Clinics & Hospitals › Europe › Ceramics › Others › Orthodontics › Academic Inst
Slide 16: Global Dental Materials Market USD (in Mn.)
GLOBAL DENTAL MATERIALS MARKET GLOBAL DENTAL MATERIALS MARKET - REVENUE DENTAL MATERIALS MARKET - FORECAST (REGION-WISE), 2015-2020 USD 8,240.30 3,3177.3 Millions USD (in Mn.) 7,839.80 491.3 7,458.20 534.4 1,400.1 CAGR | 7.0% 7,094.60 3,020.2 1,543.1 6,748.30 CAGR | 6.9% 3,252.7 6,418.50 CAGR | 9.1%
Slide 17: Key Growth Drivers in Dental Industry
KEY GROWTH DRIVERS IN DENTAL INDUSTRY The major factors favoring the dental market growth are increasing number of patients, with the dental caries, Rising Dental Disorders and periodontal diseases, which is boosting the demand for the dental materials. According to the study of the Among People Glo
Slide 18: Outlook of India: Dental Industry
OUTLOOK OF INDIA: DENTAL INDUSTRY GROWTH IN DENTAL TOURISM - India is able to spur its growth momentum in dental tourism with the implementation of advanced technology to perform procedures like implant surgery, cosmetic dentistry, orthodontics and paediatric dentistry ensuring high quality standard
Slide 19: Financial Overview
FINANCIAL OVERVIEW Image source: freepik.com Icon source: thenounproject.com 19 www.prevestdenpro.com Hem Securities Limited
Slide 20: Exponential Growth in Revenue and Profitability
EXPONENTIAL GROWTH IN REVENUE AND PROFITABILITY TOTAL REVENUE* EBITDA* CAGR 18.5% CAGR 45% 2,951.35 2,954.18 1,291.28 2,455.97 1,977.08 999.42 1,758.20 1,497.71 689.22 1,147.60 430.92 348.61 224.05 152.92 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 2015-16 2016-17 2017-18 2018-19 2019-20
Slide 21: Key Ratios: On a Continuous Financial Growth
KEY RATIOS: ON A CONTINUOUS FINANCIAL GROWTH PAT MARGIN EBITDA MARGIN 30.83% 43.71% 24.42% 20.39% 33.86% 28.06% 15.14% 21.80% 12.35% 19.83% 8.77% 14.96% 6.55% 13.33% 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 (9M) (9M) RETURN ON EQ
Slide 22: Immense Value Creation with Negligible Debt
IMMENSE VALUE CREATION WITH NEGLIGIBLE DEBT DEBT EQUITY RATIO NET DEBTS* 0.56 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 (9M) 151.79 (88.00) (302.08) (466.49) 0.31 (870.81) (1,502.78) 0.16 0.14 0.10 0.06 0.03 2015-16 2016-17 2017-18 2018-19 2019-20 2020-21 2021-22 (9M) (4,233.63) NET WO
Slide 23: Statement of Profit & Loss
STATEMENT OF PROFIT & LOSS (Rs. in lakhs) PARTICULARS Q3 FY 2022 9M FY 2022 H1 FY 2022 FY 2021 Revenue from operations 1,112.23 2,829.19 1,716.95 2,847.60 Other Income 66.52 124.99 58.47 103.74 Total Revenue 1,178.76 2,954.18 1,775.42 2,951.35 Cost of Material Consumed 252.35 727.94 475.59 798.45 Ch
Slide 24: Balance Sheet - Assets
BALANCE SHEET - ASSETS (Rs. in lakhs) ASSETS as on Dec 31, 2021 September 30, 2021 March 31, 2021 (Audited) Non-Current Assets Tangible Assets 577.99 552.75 536.23 Other Non Current Assets 334.13 237.33 171.13 Total 912.12 790.08 707.35 Current Assets Inventories 267.22 231.09 127.32 Trade receivabl
Slide 25: Balance Sheet – Liabilities
BALANCE SHEET – LIABILITIES (Rs. in lakhs) LIABILITY as on Dec 31, 2021 September 30, 2021 March 31, 2021 (Audited) Shareholders’ funds Equity Share Capital 1,200.30 1,200.30 28.50 Reserves and Surplus 4,262.46 3,875.98 2,221.10 Total 5,462.76 5,076.28 2,249.60 Non-Current Liabilities Long Term Borr
Slide 26: Disclaimer
DISCLAIMER This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute prospectus or placement memorandum or an offer to acquire any securities. No representation or warranty, express or implied is made as to, and no reli